Literature DB >> 2930331

Dysphoric mania. Clinical and biological correlates.

R M Post1, D R Rubinow, T W Uhde, P P Roy-Byrne, M Linnoila, A Rosoff, R Cowdry.   

Abstract

Patients studied at peak severity of a manic episode showed substantial degrees of depression (dysphoria) and anxiety. Compared with nondysphoric manics (n = 26), the dysphoric manics (n = 22) had a significantly greater number of previous hospitalizations, and they displayed less rapid cycling both in the year before and during the index hospitalization admission. The severity of manic dysphoria tended to correlate with the number of previous hospitalizations, a finding that was highly significant in women (n = 27). Medication-free manic patients (n = 22) had significant elevations in cerebrospinal fluid norepinephrine concentrations compared with depressed and euthymic patients and normal volunteers, and the degree of elevation correlated significantly with the degree of manic dysphoria, anger, and anxiety rated at the time of the lumbar puncture. Patients with dysphoric mania, recognized by Kraepelin to have poor prognoses, have been reported to respond poorly to lithium carbonate but may be among those who respond to carbamazepine. Clinical, biologic, and pharmacologic response characteristics of manic subgroups, particularly those with extreme dysphoric components to their illness, appear to be clinically meaningful and deserving of further investigation.

Entities:  

Mesh:

Year:  1989        PMID: 2930331     DOI: 10.1001/archpsyc.1989.01810040059009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  11 in total

Review 1.  The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations.

Authors:  Jaimee L Heffner; Jeffrey R Strawn; Melissa P DelBello; Stephen M Strakowski; Robert M Anthenelli
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

Review 2.  Revisiting the serotonin-aggression relation in humans: a meta-analysis.

Authors:  Aaron A Duke; Laurent Bègue; Rob Bell; Tory Eisenlohr-Moul
Journal:  Psychol Bull       Date:  2013-02-04       Impact factor: 17.737

Review 3.  Management options for bipolar disorder in children and adolescents.

Authors:  Arman Danielyan; Robert A Kowatch
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Treatment of bipolar mixed state with olanzapine.

Authors:  V Sharma; L Pistor
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

5.  Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder.

Authors:  S L Dubovsky; M Thomas; A Hijazi; J Murphy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

6.  Psychotic and nonpsychotic bipolar mixed states: comparisons with manic and schizoaffective disorders.

Authors:  L Dell'Osso; H S Akiskal; P Freer; M Barberi; G F Placidi; G B Cassano
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

Review 7.  The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate.

Authors:  S C Dilsaver; A C Swann; A M Shoaib; T C Bowers
Journal:  J Psychiatry Neurosci       Date:  1993-03       Impact factor: 6.186

8.  A prospective study examining the effects of gender and sexual/physical abuse on mood outcomes in patients with co-occurring bipolar I and substance use disorders.

Authors:  Christina S Meade; Leah J McDonald; Fiona S Graff; Garrett M Fitzmaurice; Margaret L Griffin; Roger D Weiss
Journal:  Bipolar Disord       Date:  2009-04-15       Impact factor: 6.744

9.  The manic-depressive mixed state: familial, temperamental and psychopathologic characteristics in 108 female inpatients.

Authors:  L Dell'Osso; G F Placidi; R Nassi; P Freer; G B Cassano; H S Akiskal
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 10.  Epidemiology, diagnosis and management of mixed mania.

Authors:  Ana González-Pinto; Ana Aldama; Fernando Mosquera; Cristina González Gómez
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.